Accelerating Medicines Partnership (AMP) in Type 2 Diabetes (U01)

 

This Funding Opportunity Announcement (FOA) invites applications for the Accelerating Medicines Partnership (AMP) in Type 2 Diabetes (T2D-GENES) consortium. The AMP T2D-GENES will build on and expand the previous work of the T2D GENES consortium. The aim of the consortium is to characterize the genetic variations in human genomic regions that have been putatively associated with type 2 diabetes (T2D) and conduct follow-up functional studies of particular genetic variants. The data coordinating center for the consortium is being solicited via the companion FOA.

Deleted 08/18/2014 (Archived.) RFA-DK-14-003 Agency: Department of Health and Human Services
Office: National Institutes of Health Cooperative Agreement Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. 07/18/2014 This program does not have cost sharing or matching requirements. NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-14-003.html FBOWebmaster@OD.NIH.GOV $3,000,000.00 Awards up to $300,000.00